The Top 5 Biosimilar Articles for the Week of January 3

Here are the top 5 biosimilar articles for the week of January 3, 2022.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of January 3, 2022.

Number 5: The top legal stories in biosimilars over the past year concerned etanercept and adalimumab biosimilars and access to insulin.

Number 4: Savings from adalimumab biosimilars, which won't enter the US market until 2023, account for a significant share of the total, investigators said.

Number 3: Patients with stage IV nonsquamous non–small cell lung cancer (NSCLC) demonstrated equivalent outcomes when treated with MYL-1402O or Avastin.

Number 2: With an FDA approval for a second insulin glargine biosimilar, the stage is set for stronger competition in 2022 with potential improved access and savings for patients.

Number 1: Biosimilars have produced more than $20 billion of savings in Europe, but more use of these agents is needed.

To read all of these articles and more, visit centerforbiosimilars.com.

Related Videos
Christine Baeder Smiling
Here are the top 5 biosimilar articles for the week of March 20, 2023.
Here are the top 5 biosimilar articles for the week of March 13th, 2023.
Michael Kleinrock
Here are the top 5 biosimilar articles for the week of March 6, 2023.
Here are the top 5 biosimilar articles for the week of February 20, 2023.
Here are the top 5 biosimilar articles for the week of February 20, 2023.
Here are the top 5 biosimilar articles for the week of February 13th, 2023.
Michael Kleinrock
Here are the top 5 biosimilar articles for the week of February 6, 2023.
Related Content
© 2023 MJH Life Sciences

All rights reserved.